Sienna Biopharmaceuticals, Inc. Announces Pricing of Initial Public Offering of Common Stock
July 26, 2017 at 7:30 PM EDT WESTLAKE VILLAGE, Calif., July 26, 2017 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA)...
top of page
A L T I T U D E
Life Science Ventures
Companies in the News
Jul 24, 2017
eFFECTOR Therapeutics Completes $38.6 Million Series C Financing
July 24, 2017 – eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulators for the treatment of cancer,...
Jun 20, 2017
BlackThorn Therapeutics To Receive Up to $8 Million in NIH Blueprint Neurotherapeutics Network Fundi
South San Francisco, Calif. – June 20, 2017 – BlackThorn Therapeutics, a clinical-stage biopharmaceutical company discovering and...
Jun 20, 2017
eFFECTOR Therapeutics to Collaborate with Pfizer and Merck KGaA, Darmstadt, Germany to Evaluate a No
SAN DIEGO, June 20, 2017 /PRNewswire/ -- eFFECTOR Therapeutics announced today it has entered into a clinical collaboration and supply...
Jun 7, 2017
BlackThorn Therapeutics Announces Innovative Clinical Collaboration Agreement with Mindstrong Health
BLACKTHORN’S BTRX-246040 NOCICEPTIN PROGRAM IS FIRST MOLECULE AND CLINICAL PROGRAM TO INCORPORATE MINDSTRONG HEALTH’S PATENTED TECHNOLOGY...
Apr 24, 2017
Sienna Biopharmaceuticals Announces $40 Million Series B Financing
WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)--Sienna Biopharmaceuticals, Inc., a privately held, clinical stage medical dermatology and...
Jan 9, 2017
Indigo’s Preliminary Commercial Data Demonstrate Significant Yield Gains for Growers with Plant Micr
Indigo™ Cotton demonstrated an average yield improvement of 11% in the target environment of West Texas Farmers experienced productivity...
Jan 6, 2017
Vir Biotechnology Launches To Cure, Treat, And Prevent Challenging Infectious Diseases Using Latest
-Former Biogen leader George Scangos will be CEO, with Vicki Sato as Chairman of the Board -Company to apply immune programming at...
Dec 6, 2016
Sienna Biopharmaceuticals Acquires Creabilis plc
Acquisition Adds Phase IIb Product, Clinical Candidates and Novel Discovery Platform to Sienna's Growing Pipeline WESTLAKE VILLAGE,...
bottom of page